Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

L19TNF

Phase 2Small molecule

PPhilogen S.p.A.

L19TNF is one of 149 small molecule programs targeting Glioma. It is currently in Phase 2.

6

Indications

8

Total Trials

6

Active Trials

148

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Basal Cell CarcinomaActive, not recruiting

OligodendrogliomaActive, not recruiting

MelanomaActive, not recruiting

GlioblastomaActive, not recruiting

Locally Advanced Basal Cell CarcinomaRecruiting

GliomaPhase 1/Phase 2

Active, not recruiting

Basal Cell CarcinomaPhase 2

Active, not recruiting

OligodendrogliomaPhase 2

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

GlioblastomaPhase 1/Phase 2

Active, not recruiting

Locally Advanced Basal Cell CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Cotellic

Taxol

L19TNF

PPhilogen S.p.A.

Zelboraf

CConrado Roberto Hoffmann Filho

GM2-KLH Vaccine

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Intron a

Opdualag

Bristol-Myers Squibb

Brenetafusp

IImmunocore Ltd

PEG-Intron

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Melanoma

NCT06284590

Q1 2029

Phase 2Not yet recruiting

Oligodendroglioma

NCT07120984

Q1 2031

Phase 2Recruiting

Locally Advanced Basal Cell Carcinoma

NCT07227350

Clinical

Trials by Indication[1]

Glioblastoma2 trials

A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

Recruiting·PPhilogen S.p.A.·Phase 1/2·NCT04573192·142 enrolled

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

Recruiting·PPhilogen S.p.A.·Phase 2·NCT06336291·90 enrolled

Advanced Solid Tumours1 trial

L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours

Completed·PPhilogen S.p.A.·Phase 1·NCT02076620·29 enrolled

Doxorubicin1 trial

Dose Finding Study of L19TNF and Doxorubicin in Patients With STS

Active, not recruiting·PPhilogen S.p.A.·Phase 1·NCT04032964·2 enrolled

Melanoma1 trial

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

Recruiting·PPhilogen S.p.A.·Phase 2·NCT06284590·162 enrolled

Oligodendroglioma1 trial

A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma

Not yet recruiting·PPhilogen S.p.A.·Phase 2·NCT07120984·52 enrolled

2 more indications

Glioma1 trial

Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse

Completed·PPhilogen S.p.A.·Phase 1/2·NCT03779230·20 enrolled

Locally Advanced Basal Cell Carcinoma1 trial

A Phase 2 Controlled Randomized Study of the Efficacy of L19IL2 or L19TNF or L19IL2/L19TNF Intralesional Injections for the Treatment of Locally Advanced Basal Cell Carcinoma (LaBCC)

Recruiting·PPhilogen S.p.A.·Phase 2·NCT07227350·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for L19TNF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L19TNF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L19TNF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Philogen S.p.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPhilogen S.p.A.

Related News